Trial Profile

A Multicenter, Randomized, and Observer-blind Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-based COVID-19 Vaccine Against Coronavirus Variants in Adults (≥ 18 Years) Who Have Been Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; AZD 1222; Tozinameran
Indications COVID 2019 infections
Focus Pharmacodynamics; Registrational
Sponsors Tianjin CanSino Biotechnology

14 Jun 2023 According to a Clinicaltrials.gov record, the trial protocol was not approved by the regulatory authorities.
14 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
28 Oct 2022 Planned End Date changed from 1 Mar 2023 to 30 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com